GRAL
GRAIL Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +9.0% ·
net new positions +16.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 110 | +3 | 19.61M | $1.34B | +13 | −10 |
| Q1 2026 | 110 | -6 | 18.56M | $959.35M | +4 | −11 |
| Q4 2025 | 117 | +2 | 17.78M | $1.52B | +3 | n/a |
| Q3 2025 | 18 | +1 | 10.99M | $649.07M | +2 | −2 |
| Q2 2025 | 15 | -1 | 10.50M | $537.63M | +1 | −2 |
| Q1 2025 | 13 | +1 | 6.08M | $155.14M | +2 | −1 |
| Q4 2024 | 12 | +2 | 5.32M | $94.90M | +3 | −1 |
| Q3 2024 | 9 | -6 | 3.74M | $51.49M | n/a | −6 |
| Q2 2024 | 15 | n/a | 4.39M | $67.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 2.08M | -4.7% | $37.12M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 1.14M | n/a | $20.29M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | AQR Capital Management ✦ | 830.72K | +71.0% | $14.83M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (passive) | 443.56K | +4.6% | $7.92M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 295.52K | +41.8% | $5.28M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 282.84K | +295.8% | $5.05M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 96.63K | New | $1.72M | 0.0% | New | 1 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 66.34K | 0.0% | $1.18M | 0.0% | Held | 3 | SEC ↗ |
| 9 | GAMCO Investors ✦ | 25.90K | -2.6% | $462,315 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 24.52K | +21.7% | $438,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 22.86K | New | $408,051 | 0.0% | New | 1 | SEC ↗ |
| 12 | Arrowstreet Capital ✦ | 11.50K | New | $205,293 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $1.72M | 0.0% |
| Wellington Management | $408,051 | 0.0% |
| Arrowstreet Capital | $205,293 | 0.0% |
Exited
| Marshall Wace | $3.53M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 9.40K shares, $485 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 6.03K sh · $830,465
Officer, Director · 7.05K sh · $964,946
Officer, Director · 2.11K sh · $293,394
Officer, Director · 400 sh · $53,247
Officer, Director · 1.00K sh · $134,384
Officer, Director · 3.40K sh · $460,508
Officer · 23.62K sh · $3.46M
Officer · 7.87K sh · $1.15M
Officer, Director · 10.00K sh · $1.10M
Officer, Director · 2.10K sh · $211,429
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology